NCT06056310 2025-09-29
Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)
EMD Serono
Phase 1 Terminated
EMD Serono
EpicentRx, Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Galera Therapeutics, Inc.
Eli Lilly and Company